EDTUTC-4 New YorkLog in Sign up

PK
Park Hotels & Resorts Inc. Common Stock
stockNYSE

Market OpenOct 5, 2026 12:09:06 PM EDT

15.40USD-0.869%(-0.13)1,104,041

15.39Bid15.40Ask0.01Spread

Pre-marketOct 5, 2026 9:29:59 AM EDT

15.53USD+0.032%(+0.00)

PK News

Day breaks

08:00 AM EDTMarea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly ·

GlobeNewswire Inc.

05:00 AM EDTAscletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 2026 ·

PR Newswire

07:00 AM EDTEASD 2026 | Ecnoglutide Demonstrates Favorable Safety Profile in Adolescents with Obesity ·

PR Newswire

01:57 AM EDTBreaking the Safety Barrier: Insilico Medicine Nominates ISM1354, the Next-Generation Small Molecule GIPR Antagonist ·

PR Newswire

08:00 AM EDTTectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT) ·

GlobeNewswire Inc.

07:30 AM EDTDecoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program ·

PR Newswire

09:55 AM EDTPark Hotels & Resorts gets bullish upgrade as RevPAR strength continues ·

Seeking Alpha

08:00 AM EDTPK CONSUMER HEALTH NAMES NEIL LISTER CEO ·

PR Newswire

11:26 AM EDTBDRX: Enrollment in Phase 3 SERENTA Trial Reaches 92 Patients ·

Zacks Small Cap Research

11:35 AM EDTMid-cap REIT momentum is building: 10 stocks in the watchlist ·

Seeking Alpha

06:00 AM EDTAccro Bioscience Announces First Patient Dosed in Phase IIb Study of AC-101 in Moderate-to-Severe Ulcerative Colitis ·

PR Newswire

07:00 AM EDTThese real estate stocks stand out for attractive valuations ·

Seeking Alpha

12:00 AM EDTRAVEN2 OPENS FRESH START SERVER "ZERO" WITH "LEGENDARY FESTIVAL" REWARDS ·

PR Newswire

08:30 AM EDTRenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer ·

GlobeNewswire Inc.